Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

Seminal Study Successfully Achieved Primary and Secondary Endpoints, Demonstrating that Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive, and Function Long-Term and Continue to Produce Insulin in the Patient for Over One Year Following Administration Without Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application and Initiate Phase 1/2 Trial as Early as This Year for SC451, a HIP-Modified, Stem Cell-Derived Therapy Designed as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Long-Term Normal Blood Glucose Without the Need for Insulin Therapy or Immunosuppression

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.